A Breakthrough in Glaucoma Treatment: The Alloflo Bio-Interventional Surgery

For patients living with glaucoma, advances in treatment can mean the difference between maintaining vision and progressive loss. At North Manhattan Eye Center, Dr. Gabriel Ferreira is at the forefront of one of the most promising innovations in glaucoma care — the Alloflo procedure by Iantrek, the world’s first bio-interventional glaucoma surgery.

Unlike traditional surgeries that rely on metallic or synthetic implants, the Alloflo procedure uses a human tissue allograft — real donor tissue — to gently create and support a new fluid-drainage pathway within the eye. This “outflow tunnel,” or cleft, is designed to help fluid exit more naturally, reducing intraocular pressure (IOP) with less trauma to the surrounding tissue.

Because the stent material is organic and biocompatible, the body is far less likely to react or scar over the new pathway. The result is a more natural, longer-lasting solution for managing glaucoma — with the potential for faster recovery and fewer complications.

Dr. Ferreira is among the top surgeons worldwide performing this cutting-edge procedure and has been part of its original research and early adoption since its inception.

“This approach changes how we think about glaucoma surgery,” says Dr. Ferreira. “By using the body’s own biological systems, we’re opening new doors for safer, more effective pressure control.”

Watch Dr. Ferreira in surgery as he performs this groundbreaking procedure at NMEC:

If you or a loved one is managing glaucoma and wants to learn whether you might be a candidate for this innovative procedure, schedule a consultation with Dr. Ferreira and the NMEC team today.